ArticleLancet regional health. Americas2025
Carbapenemases producing gram-negative bacteria surveillance in Latin America and the caribbean: a retrospective observational study from 2015 to 2020.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Better infectious disease diagnostics is crucial to tackling antimicrobial resistance.Lancet regional health. Americas · 2026Article
- The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC-antimicrobial resistance · 2026Review
- Article
- In vitro activity of aztreonam-avibactam against carbapenem-resistant Pseudomonas aeruginosa from Southern Brazil.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Metallo-beta-lactamase α-helix fragment modified peptide N10 is a multifunctional antimicrobial peptide.Microbiology spectrum · 2026Article
- Prevalence of carbapenemase production among Enterobacterales with reduced susceptibility to meropenem in patients at Hospital de Clínicas de Porto Alegre (HCPA) between 2019 and 2024.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- ConsistentAntimicrobial agents and chemotherapy · 2026Article
- Regulatory Harmonization Needs for Farm-to-Fork Bacteriophage Applications in South American Food Systems.Foods (Basel, Switzerland) · 2026Review
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Trends and drivers of multidrug-resistant bacteria incidence in 59 Chilean intensive care units, 2015-2024: a Bayesian hierarchical analysis.Lancet regional health. Americas · 2026Article
- Emergence of KPC-producingAntimicrobial agents and chemotherapy · 2026Article
- Emergence and Genomic Characterization of a Hypervirulent Klebsiella pneumoniae Isolate From a New Clone in Brazil.Microbiology and immunology · 2026Article
- Expanding Threat of Carbapenemase-ProducingbioRxiv : the preprint server for biology · 2026Article
- Exploratory Insights on Epidemiology, Genomic Features and Pangenome Analysis of NDM-1-Positive Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Co-occurrence of blaBMC microbiology · 2026Article
- Epidemiological Insights into Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Integrated Phenotypic, Proteomic (MALDI-TOF MS), and Genomic (WGS) Investigation of a Prolonged Hospital Outbreak ofAntibiotics (Basel, Switzerland) · 2026Article
- Microbiological characterization and clinical outcomes of carbapenem-resistant enterobacterales infections in a paediatric hospital in Mexico.BMC infectious diseases · 2026Observational
- Access to Reserve Antibiotics in Latin America and the Caribbean: Situation, Challenges, and Future Directions.Infection and drug resistance · 2026Review
- Temporal Trends in Antimicrobial Resistance in a Tertiary Hospital in Western Guangxi, China: A Five-Year Surveillance Study (2021-2025).Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Background: The rise of multidrug-resistant (MDR) bacteria represents a public health threat, with carbapenem resistance exacerbating this challenge. This study investigates carbapenemase-producing bacteria (CPB) across the Latin America and the Caribbean (LAC) region. Methods: A retrospective observational study was conducted across 12 LAC countries from 2015 to 2020. A total of 58,909 isolates were analyzed utilizing polymerase chain reaction (PCR) to detect key carbapenemases in Enterobacterales, Findings: 47,804/58,909 (81.14%) carbapenemases were identified, with Brazil accounting for 73% of these. The majority were reported in carbapenem-resistant Enterobacterales-CRE (65.33%; 31,230/47,804), followed by carbapenem-resistant ABC-CRAB (22.05%; 10,542/47,804), and carbapenem-resistant Interpretation: This study highlights a high prevalence of CPB in LAC, with a stable trend in Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.